Jubilant Pharmova LtdQ2 FY25Pharmaceuticals & Biotechnology

Jubilant Pharmova Ltd

Q2 FY25 Earnings Call Analysis

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Revenue guidance

Category 2

→Specialty Chemicals and Nutrition segments expected to sustain growth; Specialty to contribute 65%-70% of overall EBITDA going forward.
→Overall business is projected to grow at 20%-25% year-on-year driven by specialty and export growth.
→CDMO business pipeline is strong, with 70+ active opportunities; pharma funnel has doubled in one year.
→Agro CDMO contracts progressing; more contracts expected in coming months.
→Semiconductor segment has 12+ opportunities, with near commercial stage molecules.
→New multipurpose plants and capacity debottlenecking underway to support growth.
→Niacinamide plant commissioning to accelerate growth in human nutrition.
→Big agro CDMO order supplies to start early 2026.
→Recovery expected in Acetyl segment with improving volumes and margins.
→US and Rest of World revenues growing strongly (US +11% YoY, ROW +45% YoY).
→CAPEX of ~Rs.600 crore planned in FY’26 focusing on capacity expansions.

Category 3

→Specialty Chemicals and Nutrition segments expected to sustain strong growth, contributing ~63% revenue and 90% EBITDA.
→Specialty segment EBITDA expected to remain at 65%-70% of overall company EBITDA in steady state.
→Anticipated recovery and volume growth in Acetyls segment, with margins expected to improve.
→Double-digit volume growth anticipated in specialty portfolio and export markets including the US, Europe, and Japan.
→Lean 2.0 cost optimization program targeting Rs. 100+ crore annualized savings in FY’26.
→CDMO business pipeline expanding significantly, with large upcoming contracts expected to drive growth starting early 2026.
→Niacinamide and human nutrition segments poised for accelerated growth due to new plant ramp-up.
→Overall company EBITDA rose 29% YoY in Q1 FY’26; profit after tax increased 54% YoY.
→Capex of Rs. 600 crore planned in FY’26 to support these growth initiatives.
→Expect to reach near 70%-80% capacity utilization of Rs. 2,000 crore CAPEX by FY’27, supporting revenue ~Rs. 6,500 crore.

Get access to all 5 sections — revenue, margin, fundraise, orderbook, and capex — for Jubilant Pharmova Ltd and 1,400+ other companies.

→There is no explicit mention of any new fundraising through debt or equity in the provided transcript.
→The company indicated that the capital expenditure (CAPEX) incurred during the quarter (~Rs. 54 crore) was primarily funded through internal accruals.
→The net debt as of 30th June was Rs. 700 crore, with a stable net debt to EBITDA ratio of 1.18x.
→For FY’26, the planned CAPEX is Rs. 600 crore, but no mention of raising external funds was made.
→Overall, the company appears to be funding growth and CAPEX through internal resources rather than through fresh debt or equity as per the current disclosures.

Yes

→The CDMO business pipeline has doubled in the last year, with about 70 molecules in the funnel, representing addressable markets running into thousands of crores.
→Orders include a big $300 million agro CDMO contract, with plant construction ongoing and supplies expected to start early 2026.
→Two agro CDMO contracts were awarded last year; five to six more are in advanced stages or discussions.
→Multiple opportunities exist in pharma, agro, and semiconductor segments, with 12+ pipeline opportunities in semiconductor alone.
→The company is actively engaging with 30+ key accounts across geographies (EU, US, Japan) to convert opportunities into orders.
→Debottlenecking and capacity expansions are in progress to meet the expected demand from these orders.
→Management is confident about converting 70%-80% of pipeline opportunities over time but notes that external factors can influence timelines.

Yes

→Completed Rs. 2000 crore investment largely into specialty chemicals, including multipurpose and dedicated plants for CDMO and Fine Chemicals.
→Major dedicated plant construction in Bharuch expected to complete by end of FY'26.
→Commissioning of a new boiler at Bharuch scheduled for Q2 FY'26.
→Debottlenecking initiatives to increase capacity by 15%-20% at existing multipurpose plants in Bharuch and Gajraula.
→Detailed engineering started for a new multipurpose plant (MPP8) at Gajraula, with construction expected to begin in the next few months.
→Conversion of recently commissioned niacinamide plant into a multipurpose plant for human nutrition segment underway.
→Overall CAPEX planned at Rs. 600 crore for FY’26, primarily funded through internal accruals.
→Ongoing strategic investments to support growth in CDMO, Agro, Semiconductor segments, and specialty chemicals, including R&D enhancements.

How does Jubilant Pharmova Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Jubilant Pharmova Ltd

Rev 2Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Jubilant Pharmova Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.